Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,701,384
  • Shares Outstanding, K 361,631
  • Annual Sales, $ 8,757 M
  • Annual Income, $ -592,000 K
  • EBIT $ 2,547 M
  • EBITDA $ 3,876 M
  • 60-Month Beta 0.69
  • Price/Sales 0.31
  • Price/Cash Flow 1.02
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 56.46% ( -3.17%)
  • Historical Volatility 44.74%
  • IV Percentile 37%
  • IV Rank 13.67%
  • IV High 177.43% on 07/24/24
  • IV Low 37.30% on 05/24/24
  • Put/Call Vol Ratio 0.57
  • Today's Volume 1,468
  • Volume Avg (30-Day) 6,775
  • Put/Call OI Ratio 2.30
  • Today's Open Interest 247,059
  • Open Int (30-Day) 249,442

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 1.13
  • Number of Estimates 7
  • High Estimate 1.35
  • Low Estimate 0.90
  • Prior Year 1.15
  • Growth Rate Est. (year over year) -1.74%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.33 +1.91%
on 12/20/24
8.52 -12.27%
on 12/10/24
-0.72 (-8.79%)
since 11/20/24
3-Month
7.33 +1.91%
on 12/20/24
9.85 -24.16%
on 11/04/24
-0.56 (-6.97%)
since 09/20/24
52-Week
3.96 +88.64%
on 07/24/24
11.46 -34.82%
on 04/03/24
+0.22 (+3.03%)
since 12/20/23

Most Recent Stories

More News
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a...

BHC.TO : 10.71 (+0.66%)
BHC : 7.47 (+1.08%)
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day

LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation...

BHC.TO : 10.71 (+0.66%)
BHC : 7.47 (+1.08%)
Bausch Health Appoints New Chief Medical Officer and Head of R&D

LAVAL, QC / ACCESSWIRE / December 2, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is pleased to announce the appointment of Jonathan Sadeh M.D., M.Sc as Executive Vice President, Chief Medical...

BHC.TO : 10.71 (+0.66%)
BHC : 7.47 (+1.08%)
Bausch Health and Salix to Present at the American Association for the Study of Liver Disease (AASLD) the RED-C Phase 3 Study Design for a New Investigational Product Designed to Address Serious Complications of Cirrhosis

Next generation product may increase gastrointestinal luminal concentration while limiting system exposure

BHC.TO : 10.71 (+0.66%)
BHC : 7.47 (+1.08%)
Bausch Health to Announce Third Quarter 2024 Results on October 30, 2024

LAVAL, QC / ACCESSWIRE / October 9, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release third quarter 2024 financial results after market close on Wednesday, October 30, 2024. Bausch Health...

BHC.TO : 10.71 (+0.66%)
BHC : 7.47 (+1.08%)
Bausch Health: A Buyout Bid Could Be the Ticket to Unlock Value

The potential sale of Bausch + Lomb, Bausch Health's eye care business, could result in a financial gain for the company by reducing its debt burden.

ALC : 84.76 (+0.69%)
BLCO : 18.00 (+0.28%)
BHC : 7.47 (+1.08%)
Here's Why Bausch Health Stock Gained 14.7% in a Week

Shares of Bausch Health, Inc. BHC gained 14.7% in a week on reports of refinancing its debt to enable the impending sale of its eye care company, Bausch + Lomb BLCO. The industry declined 0.6% during this...

KRYS : 164.83 (+2.49%)
FULC : 4.35 (+7.94%)
BLCO : 18.00 (+0.28%)
BHC : 7.47 (+1.08%)
Health Canada Approves (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide) Triple-Combination Topical Treatment for Acne Vulgaris in Patients 12 Years of Age and Older

LAVAL, QC / ACCESSWIRE / September 11, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) today announced the approval by Health Canada of PrCABTREOTM (clindamycin...

BHC : 7.47 (+1.08%)
BHC.TO : 10.71 (+0.66%)
Bausch Health Responds to Market Rumors

LAVAL, QC / ACCESSWIRE / July 24, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company") has become aware of a news article issued by Reorg® today, citing unnamed sources.

BHC : 7.47 (+1.08%)
BHC.TO : 10.71 (+0.66%)
Why Bausch Health Companies Stock Dived by More Than 7% Today

A large red number on the bottom line attracted the wrong kind of investor attention for the company.

BHC : 7.47 (+1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Bausch Health Companies Inc. develops, manufactures and markets a wide array of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products along with medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices in the therapeutic...

See More

Key Turning Points

3rd Resistance Point 7.86
2nd Resistance Point 7.73
1st Resistance Point 7.60
Last Price 7.47
1st Support Level 7.34
2nd Support Level 7.20
3rd Support Level 7.07

See More

52-Week High 11.46
Fibonacci 61.8% 8.59
Fibonacci 50% 7.71
Last Price 7.47
Fibonacci 38.2% 6.82
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar